Group 1 - AMN Healthcare Services (AMN) closed at $21.18, with a 2% gain over the past four weeks, and a mean price target of $27.39 suggests a 29.3% upside potential [1] - The average price targets from analysts range from $24.00 to $33.00, indicating a potential increase of 13.3% to 55.8%, with a standard deviation of $3.88 reflecting the variability of estimates [2] - Analysts show strong agreement that AMN will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for AMN's current year earnings has increased by 6.3% over the past month, with no negative revisions [12] - AMN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [14]

Core Insights - The Zacks Rank system emphasizes earnings estimates and revisions to identify winning stocks, while also considering trends in value, growth, and momentum for strong stock picks [1][2] Value Investing - Value investing is highlighted as a preferred strategy for identifying strong stocks across various market conditions, focusing on traditional analysis of key valuation metrics to find undervalued stocks [2] AMN Healthcare Services - AMN Healthcare Services (AMN) is identified as a strong value stock, currently holding a Zacks Rank of 2 (Buy) and a Value grade of A, indicating its attractiveness to value investors [3] - AMN has a price-to-book (P/B) ratio of 1.17, which is favorable compared to the industry average P/B of 1.58, suggesting that the stock is undervalued [4] - The historical P/B ratio for AMN has ranged from a high of 2.95 to a low of 0.95, with a median of 1.40 over the past year, reinforcing its current valuation status [4] - The combination of AMN's strong earnings outlook and its valuation metrics positions it as an impressive value stock at this time [5]

Core Insights - AMN Healthcare has elected Celia Huber to its Board of Directors, bringing over 30 years of experience in healthcare strategy and governance [1][3] - Huber's expertise includes advising healthcare systems and payors on strategy, risk, and performance, aligning with AMN's mission to enhance workforce solutions [2][3] Company Overview - AMN Healthcare is recognized as a leader in total talent solutions for healthcare organizations in the U.S., focusing on solving workforce challenges to improve clinical outcomes [7] - The company offers a comprehensive network of healthcare professionals and a customizable suite of workforce technologies [7] Leadership Background - Celia Huber is a Senior Partner at McKinsey & Company, leading the Board Services Practice in North America, and has extensive experience in governance and organizational transformation [3][5] - Huber has served on various boards and committees, including the AltaMed Foundation and the California Business Roundtable, showcasing her commitment to healthcare and community service [5]

Group 1 - AMN Healthcare Services, Inc. reported high demand in therapy and imaging specialties, indicating a positive trend in the healthcare sector [1] - The company experienced a decrease in interest expenses, attributed to reductions in net debt [1] Group 2 - The overall normalization in the industry suggests a potential stabilization of market conditions, which may benefit AMN Healthcare's operations [1]

Core Insights - The average time to schedule a physician appointment in 15 major metropolitan areas has increased by 19% since 2022 and by 48% since 2004, now averaging 31 days [1][2][3] Appointment Wait Times - The survey indicates that average wait times for various specialties are as follows: - Obstetrics/Gynecology: 42 days, up 33% since 2022 and up 79% since 2004 [9] - Gastroenterology: 40 days (newly added in 2025) [9] - Dermatology: 36.5 days, up 6% since 2022 and up 50% since 2004 [9] - Cardiology: 33 days, up 23% from 2022 and up 74% since 2004 [9] - Family Medicine: 23.5 days, up 14% since 2022 and up 16% since 2009 [9] - Orthopedic Surgery: 12 days, down 29% since 2022 and down 29% since 2004 [9] Geographic Variations - Boston has the longest average wait time at 65 days, while Atlanta has the shortest at 12 days [4] - Wait times can vary significantly by specialty and metropolitan area, with some appointments taking as long as 291 days for dermatology in Portland, Oregon [6] Physician Acceptance Rates - 82% of physicians in the surveyed metropolitan areas accept Medicare, with Boston having the highest acceptance rate at 94% and Atlanta the lowest at 68% [7] - Only 53% of physicians accept Medicaid, with Detroit having the highest acceptance at 85% and New York the lowest at 28% [7][8] Implications - The increasing wait times for physician appointments indicate a growing shortage of physicians in the U.S., particularly in densely populated areas [3][5]

Core Insights - The nursing profession is under significant pressure, with 1 in 3 nurses eligible for retirement and high levels of burnout reported among the workforce [1][2][3] Survey Findings - 75% of nurses express satisfaction with their career choice, a slight increase from previous years, but 58% report feeling burned out most days [2][3] - 64% of nurses experience compassion fatigue, and 33% are eligible for retirement this year [2][7] - 49% of nurses believe flexible work hours would encourage them to remain in the profession longer [3][4] Recommendations for Improvement - Healthcare administrators are urged to invest in sustainable solutions that enhance nurses' work-life balance and job satisfaction [4] - Suggested strategies include advanced scheduling technologies, mentorship models, financial incentives, and workplace violence prevention measures [4][6] - 81% of nurses agree that flexible schedules would improve working conditions, highlighting the need for systemic changes in the industry [7]

Core Viewpoint - AMN Healthcare Services, Inc. reported a significant decline in adjusted earnings per share and revenues for the first quarter of 2025, although the adjusted EPS exceeded consensus estimates. The company anticipates continued revenue declines across all segments in the upcoming quarter, raising concerns about its financial performance [1][10][12]. Revenue Summary - AMN Healthcare's total revenues for Q1 2025 were $689.5 million, reflecting a 16% decrease year over year, but surpassing the Zacks Consensus Estimate by 2.7% [2]. - The Nurse and Allied Solutions segment generated revenues of $413.3 million, down 20.4% year over year, with travel nurse staffing revenues declining by 36% [4]. - The Physician and Leadership Solutions segment reported revenues of $174.1 million, a decrease of 7.8% year over year, with locum tenens revenues down 3% [5]. - The Technology and Workforce Solutions segment's revenues totaled $102.2 million, down 9.4% year over year, although language interpretation services saw a 5% increase [6]. Margin Analysis - AMN Healthcare's gross profit fell by 23.1% year over year to $198.1 million, with a gross margin contraction of 264 basis points to 28.7% [7]. - Adjusted operating profit was $50.4 million, reflecting a 39% decline from the prior year, and the adjusted operating margin contracted 276 basis points to 7.3% [7]. Financial Position - At the end of Q1 2025, AMN Healthcare had cash and cash equivalents of $55.8 million, up from $10.6 million at the end of 2024. Total debt decreased to $1 billion from $1.060 billion [8]. - Net cash provided by operating activities was $92.7 million, compared to $81.4 million a year ago [8]. Guidance - For Q2 2025, AMN Healthcare expects revenues to be in the range of $645 million to $660 million, indicating an 11-13% decline compared to the previous year [10]. - The company anticipates a revenue decline of 14-17% in the Nurse and Allied Solutions segment, 8-10% in the Technology and Workforce Solutions segment, and 5-7% in the Physician and Leadership Solutions segment [11]. Market Reaction - Following the earnings report, AMN Healthcare's shares gained nearly 9.2% in after-hours trading, indicating a positive market reaction despite the overall disappointing financial performance [2].

Core Insights - AMN Healthcare Services reported a revenue of $689.53 million for the quarter ended March 2025, reflecting a 16% decline year-over-year, while EPS was $0.45 compared to $0.97 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $671.3 million by 2.72%, and the EPS surpassed the consensus estimate of $0.19 by 136.84% [1] Financial Performance Metrics - AMN Healthcare's stock has returned -5.3% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change, and currently holds a Zacks Rank 3 (Hold) [3] - In the Physician and leadership solutions segment, Days Filled were reported at 51.34 million, slightly below the average estimate of 51.95 million, while revenue per day filled was $2.74 million, exceeding the estimated $2.63 million [4] - Revenue from Physician and leadership solutions was $174.07 million, surpassing the average estimate of $171.10 million, but showing a year-over-year decline of 7.8% [4] - Revenue from Nurse and allied solutions was $413.26 million, exceeding the average estimate of $397.20 million, but reflecting a significant year-over-year decline of 20.4% [4] - Revenue from Technology and workforce solutions was $102.21 million, slightly below the estimated $103 million, marking a 9.4% decrease compared to the year-ago quarter [4] - Segment operating income for Nurse and allied solutions was $32.24 million, above the estimated $30.79 million, while for Technology and workforce solutions it was $35.25 million, below the estimated $37.97 million [4] - Segment operating income for Physician and leadership solutions was $14.46 million, falling short of the estimated $17.29 million [4]

AMN Healthcare Services (AMN) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 136.84%. A quarter ago, it was expected that this health care staffing company would post earnings of $0.52 per share when it actually produced earnings of $0.75, delivering a surprise of 44.23%.Over the las ...

Financial Performance - Revenue for Q1 2025 was $689.5 million, a decrease of 16% compared to $820.9 million in Q1 2024[16] - Gross profit for Q1 2025 was $198.1 million, down 23% from $257.5 million in Q1 2024[16] - Net loss for Q1 2025 was $1.1 million, compared to a net income of $17.3 million in Q1 2024[16] - The company reported a comprehensive loss of $1.0 million for Q1 2025, compared to a comprehensive income of $17.4 million in Q1 2024[16] - Total revenue for the three months ended March 31, 2025, was $689,533, a decrease of 15.9% compared to $820,878 for the same period in 2024[46] - Gross profit for Q1 2025 was $198,120, down 23.0% from $257,506 in Q1 2024[46] - Segment operating income for Q1 2025 was $81,950, a decline of 31.6% from $119,834 in Q1 2024[46] - Revenue decreased 16% to $689.5 million for the three months ended March 31, 2025, from $820.9 million for the same period in 2024, with the largest decline in the nurse and allied solutions segment[84] Cash Flow and Liquidity - Cash and cash equivalents at the end of Q1 2025 were $55.8 million, significantly up from $10.6 million at the end of Q4 2024[14] - Cash flows from operating activities for Q1 2025 were $92.7 million, an increase from $81.4 million in Q1 2024[22] - Net cash provided by operating activities increased to $92.7 million for the three months ended March 31, 2025, compared to $81.4 million in 2024[93] - Net cash used in investing activities for Q1 2025 was $26.0 million, compared to $21.4 million in Q1 2024, primarily due to a net purchase of investments of $14.5 million[98] - Net cash used in financing activities during Q1 2025 was $61.2 million, an increase from $39.0 million in Q1 2024, due to repayments of $95.0 million under the Senior Credit Facility[99] Assets and Liabilities - Total current assets increased to $627.4 million as of March 31, 2025, from $594.9 million at December 31, 2024[14] - Total liabilities decreased to $1.68 billion as of March 31, 2025, from $1.71 billion at December 31, 2024[14] - The company’s total stockholders' equity increased to $715.1 million as of March 31, 2025, from $706.6 million at December 31, 2024[14] - As of March 31, 2025, total cash, cash equivalents, and restricted cash amounted to $117,445 million, an increase from $97,473 million as of December 31, 2024[30] - The allowance for expected credit losses for accounts receivable decreased to $23,273 million as of March 31, 2025, from $31,796 million as of December 31, 2024[33] Segment Performance - The nurse and allied solutions segment revenue comprised 60% of total consolidated revenue for the three months ended March 31, 2025, down from 63% in the same period last year[72] - The physician and leadership solutions segment revenue increased to 25% of total consolidated revenue for the three months ended March 31, 2025, compared to 23% for the same period last year[73] - The technology and workforce solutions segment revenue accounted for 15% of total consolidated revenue for the three months ended March 31, 2025, up from 14% in the same period last year[74] - Travel nurse staffing revenue decreased to $215,447 in Q1 2025 from $334,369 in Q1 2024, representing a decline of 35.5%[46] - International nurse revenue totaled $33,872 in Q1 2025, down 31.4% from $49,469 in Q1 2024[47] - Nurse and allied solutions segment revenue decreased 20% to $413.3 million, primarily due to a 22% decrease in the average number of travelers on assignment[84] - Physician and leadership solutions segment revenue decreased 8% to $174.1 million, with a 10% decrease in the number of days filled impacting revenue[85] - Technology and workforce solutions segment revenue decreased 9% to $102.2 million, primarily due to a decline in VMS and outsourced solutions businesses[86] Operational Metrics - Operating expenses for Q1 2025 were $185.6 million, a reduction of 15% from $217.6 million in Q1 2024[16] - Selling, general and administrative expenses were $147.7 million, representing 21.4% of revenue, a slight increase from 21.3% in the previous year[90] - Days Sales Outstanding (DSO) remained stable at 55 days as of March 31, 2025, unchanged from December 31, 2024, but improved from 64 days in Q1 2024[97] - The average number of travelers on assignment in the first quarter decreased due to lower demand, with bill rates increasing slightly from the prior quarter[77] - Demand for locum tenens staffing in the physician and leadership solutions segment declined in the first quarter compared to both the prior year and prior quarter[78] Accounting and Reporting - The company adopted the new segment reporting standard effective for the fiscal year ended December 31, 2024, which requires enhanced disclosures about significant segment expenses[27] - The company is evaluating the impact of new accounting standards issued by the FASB, which may affect future disclosures[102][103] - The company recognized cumulative upward adjustments of $14,033 million and cumulative downward adjustments of $19,860 million related to its equity investment as of March 31, 2025[60] - The company has no material impairment charges recorded during the three months ended March 31, 2025 and 2024[61] Credit and Financing - The company has a $750,000 secured revolving credit facility, with an increased consolidated net leverage ratio covenant for the year ending December 31, 2025[49] - As of March 31, 2025, $150.0 million was drawn from a $750.0 million secured revolving credit facility, with $579.6 million available[94] - The company released $25,000 million of restricted cash in January 2025 to repay a portion of outstanding borrowings under the Senior Credit Facility[30] - The company entered into a fourth amendment to its credit agreement on November 5, 2024, increasing the consolidated net leverage ratio covenant for the year ending December 31, 2025[100] Miscellaneous - No shares of common stock were repurchased during the three months ended March 31, 2025[117] - There were no defaults upon senior securities reported[118] - Mine safety disclosures were not applicable for the reporting period[119] - No directors or officers adopted or modified any trading arrangements during the three months ended March 31, 2025[120] - The report includes various exhibits related to securities and performance restricted stock unit agreements[121]